Drugs / RP4010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03119467 | May 2017 → Nov 2019 | lymphoma | Rhizen Pharmaceuticals SA | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP4010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03119467 ↗ |